Jeffrey Leflein - Concepedia

Author

Jeffrey Leflein

Also Known As

J G Leflein, J LEFLEIN, J. Leflein, J.G. Leflein, JEFFREY LEFLEIN, Jeffrey G. Leflein, Jeffrey Leflein, Kamelia Vekovska

Publications

965

Citations

H-Index

Concepts

All Affiliations

Sanofi (United States)Regeneron (United States)Sanofi (France)AstraZeneca (United States)Environmental Research Institute of Michigan

About

Jeffrey Leflein is an author at Sanofi (United States) specializing in medicine, asthma, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	656
2	Allergy	3	3	213
3	Allergy Medicine	2	2	199
4	Pharmacology	1	1	19
5	Pulmonary Disease	1	1	168

Jeffrey Leflein

Publications

825

Citations

H-Index

Page 1

	Year	Citations
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, The Lancet AsthmaUncontrolled Atopic DermatitisAtopic DermatitisPediatricsClinical Dermatology	2022	242
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial Tim Harrison, Pascal Chanez, Francesco Menzella, The Lancet Respiratory Medicine AsthmaSevere Eosinophilic AsthmaAllergyInflammatory Lung DiseaseAllergy Medicine	2020	168
Nebulized Budesonide Inhalation Suspension Compared With Cromolyn Sodium Nebulizer Solution for Asthma in Young Children: Results of a Randomized Outcomes Trial Jeffrey Leflein, Stanley J. Szefler, Kevin R. Murphy, PEDIATRICS	2002	76
Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma James E. Fish, Jill P. Karpel, Timothy Craig, Journal of Allergy and Clinical Immunology AsthmaSevere Persistent AsthmaHealth-related QualityRespiratory FunctionPulmonary Pharmacology	2000	72
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials Marcus Maurer, Luís Felipe Ensina, Ana M. Giménez‐Arnau, The Lancet RheumatologyClinical TrialsClinical DermatologyDermatologyMedicine	2023	58
Comparable Efficacy of Administration with Face Mask or Mouthpiece of Nebulized Budesonide Inhalation Suspension for Infants and Young Children with Persistent Asthma Michael Mellon, Jeffrey Leflein, Karen Walton–Bowen, American Journal of Respiratory and Critical Care Medicine AsthmaAsthma SymptomsPediatricsPediatric Lung DiseaseYoung Children	2000	52
Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study Eli O. Meltzer, Jon E. Stahlman, Jeffrey Leflein, Clinical Therapeutics AsthmaFluticasone FuroateAllergyAllergy MedicineMedicine	2008	31
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase <scp>II</scp> Study Sayantani Sindher, Kari C. Nadeau, R. Sharon Chinthrajah, Allergy	2024	26
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy R. Sharon Chinthrajah, Sayantani Sindher, Kari C. Nadeau, Allergy	2024	25
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy Renaud Louis, Tim Harrison, Pascal Chanez, The Journal of Allergy and Clinical Immunology In Practice	2023	19

Page 1